PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype by Guadagno, Elia et al.
Oncotarget59282www.impactjournals.com/oncotarget
PATZ1 is a new prognostic marker of glioblastoma associated 
with the stem-like phenotype and enriched in the proneural 
subtype
Elia Guadagno1, Michela Vitiello2, Paola Francesca2, Gaetano Calì2, Federica 
Caponnetto3, Daniela Cesselli3, Simona Camorani2, Giorgio Borrelli1, Marialuisa 
Califano1, Paolo Cappabianca4, Claudio Arra5, Elvira Crescenzi2, Laura Cerchia2, 
Maria Laura Del Basso De Caro1 and Monica Fedele2
1Department of Advanced Biomedical Sciences, Pathology Section, University of Naples Federico II, 80131 Naples, Italy
2Institute of Experimental Endocrinology and Oncology (IEOS) “Gaetano Salvatore”, National Council of Research, 80131 
Naples, Italy
3Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy
4Division of Neurosurgery, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of 
Naples Federico II, 80131 Naples, Italy
5Department of Experimental Oncology, National Cancer Institute “Fondazione Giovanni Pascale”, IRCCS, 80131 Naples, Italy
Correspondence to: Monica Fedele, email: mfedele@unina.it, monica.fedele@cnr.it 
Maria Laura Del Basso De Caro, email: marialaura.delbasso@unina.it
Keywords: glioma, glioma stem cells, PATZ1, tumor heterogeneity, biomarker
Received: January 18, 2017    Accepted: June 19, 2017    Published: July 25, 2017
Copyright: Guadagno et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Glioblastoma (GBM), the most malignant of the brain tumors, has been classified 
on the basis of molecular signature into four subtypes: classical, mesenchymal, 
proneural and neural, among which the mesenchymal and proneural subtypes have 
the shortest and longest survival, respectively. Here we show that the transcription 
factor PATZ1 gene is upregulated in gliomas compared to normal brain and, among 
GBMs, is particularly enriched in the proneural subtype and co-localize with stemness 
markers. Accordingly, in GBM-derived glioma-initiating stem cells (GSCs) PATZ1 is 
overexpressed compared to differentiated tumor cells and its expression significantly 
correlates with the characteristic stem cell capacity to grow as neurospheres in vitro. 
Interestingly, survival analysis demonstrated that PATZ1 lower levels informed poor 
prognosis in GBM and, specifically, in the proneural subgroup, suggesting it may 
serve a role as diagnostic and prognostic biomarker for intra-subtype heterogeneity 
of proneural GBM. We also show that PATZ1 suppresses the expression of the 
mesenchyme-inducer CXCR4, and that PATZ1 and CXCR4 are inversely correlated 
in GSC and proneural GBM. Overall these findings support a central role of PATZ1 in 
regulating malignancy of GBM.
INTRODUCTION
Glioblastoma (GBM) is the most frequent primary 
malignant brain tumor and is one of the most aggressive 
neoplasms among the human cancers [1]. It is characterized 
by dismal prognosis with median survival of 16–19 months 
despite multimodal treatment including surgical resection 
followed by combined radiochemotherapy [2]. In spite of 
enormous efforts towards understanding the molecular basis 
of the disease and the development of novel therapeutic 
strategies, only limited advances have been achieved and 
there is a pressing need to identify proteins and signalling 
pathways that can serve as new targets for an improved 
treatment of GBM. The identification of brain tumour 
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stem-like cells [3], in both adult and pediatric malignant 
gliomas, has provided new insights into the biology of 
malignant glial tumours rendering these cells a potentially 
valuable therapeutic target. Indeed, a major drawback in 
the treatment of GBM is its resistance against standard 
therapeutic approaches, and current data attribute the 
resistance against both γ-irradiation and chemotherapeutic 
alkylating agent Temozolomide to the cancer stem cells [4]. 
Therefore, therapeutic targets in glioma-initiating stem cells 
(GSCc) are a focus of increasing interest to improve the 
GBM outcome.
Systematic gene expression and sequencing of 
GBM (WHO grade IV gliomas) have revealed a great 
heterogeneity of this disease with at least two major 
tumor subgroups (proneural and mesenchymal) and two 
other intermediate possible groups (classical/proliferative 
and neural) [5–7]. Among them, the proneural subtype is 
characterized by a stem-like signature and cells with a full 
stem phenotype [8], TP53 mutations and unresponsiveness 
to aggressive chemo- and radio- treatments [7].
All normal tissues host a small population of stem 
cells. These are “initiating cells’ with the unique ability 
to proliferate and differentiate into a variety of other 
cells depending on the tissue in which they are located 
in the body. In the brain, neogenesis of mature cells 
persists throughout adult life within discrete regions, 
primarily in the dentate gyrus of the hippocampus 
and in the subventricular zone of the forebrain lateral 
ventricles. The emerging hypothesis is that alterations 
in the cellular and genetic mechanisms that control adult 
neurogenesis might contribute to brain tumorigenesis. 
The main implication of continued adult neurogenesis is 
the presence of undifferentiated, mitotically active stem 
and progenitor cells within discrete regions of the mature 
brain. These populations might function as a source of cells 
for transformation, giving rise to GSCs [9]. Despite the 
stem cell population within a tumour represents a minor 
subpopulation (only 2% of cancer cells), it is responsible for 
tumor maintenance and progression, and it phenocopies the 
original tumour in rodent xenograft models. Depletion of 
the cancer stem cell population greatly impairs the potential 
of the bulk tumours to initiate xenograft tumour formation 
and leads to prolonged survival of tumour-bearing mice 
[10]. While the suitability of GSCs as therapeutic targets has 
been recently validated in vivo [11], the molecular signalling 
pathways orchestrating the biology of GSCs, as well as of 
the other cancer stem cells, remain to be elucidated.
It has been recently shown that the C2H2 zinc finger 
protein PATZ1 (POZ, AT-hook and Zinc-finger 1) is an 
important regulator of pluripotency in embryonic stem 
cells, directly involved in the regulation of pluripotency 
master genes, such as Pou5f1 and Nanog, which together 
with Sox2 are necessary for maintaining self renewal 
and pluripotency [12]. A PATZ1 role in neural stem 
cells has also been suggested by our previous studies 
showing it is highly expressed in actively proliferating 
neuroblasts of the periventricular and subventricular 
neocortical neuroepithelium, and Patz1-knockout mice 
have proliferative defects of the subventricular zone [13]. 
PATZ1 is a member of the POK (POZ and kruppel-like 
zinc finger) family, a unique group of transcription factors 
playing key roles in development and cancer through their 
involvement in a variety of cellular processes, including cell 
proliferation, senescence and apoptosis [14]. PATZ1 itself 
has been implicated in all these processes [13, 15–20]. 
In addition, several studies indicate a role of PATZ1 in 
carcinogenesis, sometimes working as a tumour suppressor 
and sometimes as an oncogene, depending on the cellular 
context [16–23]. In human brain tumour cells PATZ1 has 
been found to be included in the SOX2-interactome [24], 
and targeting of PATZ1 by siRNA in human GBM cell lines 
resistant to conventional chemotherapy, increases their 
sensitivity to apoptotic stimuli [17].
Here we characterized the expression of PATZ1 in 
human gliomas showing it is overexpressed compared to 
normal brain and is significantly enriched in the proneural 
GBM subtype, where it behaves as a valuable prognostic 
marker. We also show that PATZ1 protein in GBM co-
localizes with stem cell markers, is increased in GBM-
derived stem cells compared with tumor differentiated 
cells, and correlates with the capacity of these cells to 
grow as spheres. Finally, we show that in GBM and GBM-
derived cells PATZ1 expression negatively correlates with 
the expression of the G-protein coupled receptor and 
mesenchyme inducer CXCR4, suggesting a role of PATZ1 
in suppressing the mesenchymal subtype.
RESULTS
PATZ1 is expressed in human gliomas and is 
enriched in the proneural subtype
Using paraffin embedded sections generated 
from surgical specimens collected at the Department of 
Advanced Biomedical Sciences, Pathology Section, of 
the University of Naples Federico II, we analysed by 
immunohistochemistry PATZ1 expression in 45 grade IV 
GBM, 22 oligodendrogliomas (10 grade III and 12 grade 
II) and 26 perilesional normal brain parenchymas. Of 45 
GBM patients included in the study, 30 were males and 
15 females, aged between 26 and 81 years. The lesion was 
mainly localized in the temporal lobe in 22 cases, parietal 
in 11 cases, frontal in 9 cases, occipital in 2 cases and 1 
in the corpus callosum (Supplementary Table 1). Of 22 
oligodendroglioma patients 15 were males and 7 females, 
aging from 22 to 69 years. 14 cases were frontal, 4 
temporal, 3 occipital and 1 was an intramedullary metastasis 
(Supplementary Table 2).
We have observed that PATZ1 protein is expressed in 
neurons (mainly in the nucleus) but not in glial cells of all 
perilesional normal brain tissues (Figure 1A), whereas it is 
expressed in a high percentage of GBM (69%) with a main 
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nuclear, but sometimes cytoplasmic localization (Figure 
1B, Supplementary Table 1) and oligodendrogliomas 
(54%) (Supplementary Table 2). Among positive samples, 
PATZ1 immunoreactivity was variable in both GBM and 
oligodendrogliomas, including samples scored + (< 10%), 
++ (>10% <50%), +++ (≥ 50%). Of 31 GBM positive for 
PATZ1 staining, 17 displayed +, 9 ++ and 5 +++ score 
(Figure 2A–2D, Supplementary Table 1). Among the 12 
oligodendrogliomas expressing PATZ1, 4 cases had +, 
5 ++ and 3 +++ score (Figure 2E–2H, Supplementary 
Table 2). Among the assessed clinicopathological 
features of GBM (age, gender, site), a high significant 
correlation and a trend to be correlated with PATZ1 
expression was present in the male gender (p = 0.0028) 
and younger patients (p = 0.0695), respectively. Moreover, 
a statistically significant correlation was observed between 
PATZ1 immunoreactivity and grading (p = 0.0286) in 
oligodendrogliomas (Table 1).
By analysing public datasets through the R2: 
genomic Analysis and Visualization platform (http://
r2.amc.nl), we confirmed in an independent sample 
cohort of 6 adult non diseased brains, 26 GBMs and 21 
oligodendrogliomas [25] that PATZ1 is significantly 
more expressed in gliomas (including GBMs and 
oligodendrogliomas) compared to non diseased brain 
samples (Figure 3A). Moreover, in a data set from the 
Tumor Cancer Genomic Atlas (TCGA), including 85 
samples, sub-classified in classical (n = 17), mesenchymal 
(n = 27), neural (n = 17) and proneural (n = 24) GBM, 
we found that PATZ1 expression specifically correlates 
with the molecular subtype, being highest in proneural 
and lowest in mesenchymal subtype, with significant 
differences between each subtype (Figure 3B). 
Consistently, by studying the gene signature correlated 
with the expression of PATZ1 in the context of GBM, 
we found that PATZ1 expression positively associates 
with proneural genes, including SOX2, OLIG2, DLL3, 
NOTCH1, PDGFRα and many others, while negatively 
associates with the mesenchymal marker CD44 and many 
other genes characterizing the mesenchymal signature 
(Table 2 and Supplementary Table 3).
Taken together protein and gene expression data, 
PATZ1 is overexpressed in gliomas compared to normal 
glia and appears as a specific biomarker of the proneural 
GBM subtype.
PATZ1 is preferentially expressed in glioma stem 
cells
It has been recently reported that a proneural-
like gene expression signature is characteristic of GSCs 
characterized by a full stem phenotype (Gsf lines), 
growth as floating spheres, CD133 expression and 
multipotency, while a mesenchymal-like gene expression 
signature is associated with GSCs characterized by a 
restricted stem phenotype (Gsr lines), adherent growth, 
no CD133 expression and limited differentiation [8, 
26, 27]. Consistently, by analysing the expression 
profiles of the 9 GSCs and relative sub-clones 
isolated and characterized by Günter and colleagues 
(4 with Gsf phenotype and 5 with Gsr phenotype) 
we found that PATZ1 is significantly enriched in 
Gsf-GSCs compared with Gsr-GSCs (Figure 3C). 
The association of PATZ1 expression with CD133 
expression was further confirmed by the analysis of two 
separate experimental datasets consisting of cell lines 
established from 7 GBMs, 2 oligoastrocytomas and 5 
normal foetuses plus primary biopsies from 6 normal 
brains [28], and 8 fresh primary and non cultured GBMs 
[29], where PATZ1 expression is highly correlated 
with that of PROM1 (the gene encoding prominin-1/
CD133) (Figure 3D), and is significantly enriched in 
the CD133+ compared to the CD133- subpopulation 
(Figure 3E). Consistently, in these cells lines PATZ1 also 
Figure 1: Immunohistochemical detection of PATZ1 in human GBM and perilesional normal cortex. (A) Perilesional 
normal cortex: only neurons stain positively, mainly in the nucleus, while glial cells are negative. (B) Representative GBM: most of 
neoplastic cells are positive. Original magnification: 40x.
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correlates with markers of oligodendrocyte precursor 
cells, including SOX8, OLIG1, OLIG2, and NKX2.2, and 
of the proneural phenotype, such as DLL3, OLIG2 and 
SOX2 (Supplementary Table 4). All together these results 
indicate that PATZ1 is preferentially expressed in GSCs in 
comparison with matched non-GSCs, and is particularly 
enriched in proneural versus mesenchymal subtype.
To validate the in silico results, we analyzed 
PATZ1 expression in 6 GSCs (3 growing in adhesion and 
3 growing as spheres in laminin-coated dishes) isolated 
from patients affected by GBM in comparison with 
matched non-stem tumor cells (Figure 4A). The results 
confirmed an enriched expression of PATZ1 in stem 
versus non-stem matched samples (P < 0.05; Figure 4B). 
The differences do not reach the statistical significance 
if we consider each group (sphere forming and growing 
in adhesion GSCs) singularly, likely because of the low 
number of samples, but they have a trend to be higher 
in GSCs compared to matched non-stem tumor cells 
(data not shown). Moreover, PATZ1 expression was 
also analyzed in 5 more GBM-derived GSCs, for a total 
of 11 GSCs, which were sub-divided in two groups on 
the basis of their growth capacity in laminin-coated 
dishes (sphere/adherent). As shown in Figure 4C, and 
consistently with data shown in Figure 3C, PATZ1 
expression was highly enriched in GSCs growing as 
spheres compared to GSCs growing adherent (P < 0.01). 
All isolated GSCs, independently from their modality 
to grow in laminin-coated dishes, expressed markers of 
stemness, as confirmed by immunofluorescence analysis 
(Figure 4D), at higher levels compared with matched 
DIFF cells (data not shown). Immunofluorescence 
analysis confirmed expression of PATZ1 in GSC growing 
either as spheres or in adhesion and their colocalization 
Table 1: Fisher’s exact test: clinicopathological features and PATZ1 expression
Variables PATZ1 expression
GBM n. +/++/+++ - p
Age 45
 <60 11 10 (91%) 1 (9%) 0.0695
 ≥60 34 21 (62%) 13 (38%)
Gender 45
 Males 30 27 (90%) 3 (10%) 0.0028
 Females 15 7 (47%) 8 (53%)
Site 42
 Temporal 22 14 (64%) 8 (36%) 0.5586
 Parietal 11 9 (82%) 2 (18%)
 Frontal 9 6 (67%) 3 (33%)
Oligodendrogliomas
Age 22
 <60 17 9 (53%) 8 (47%) 0.7805
 ≥60 5 3 (60%) 2 (40%)
Gender 22
 Males 15 9 (60%) 6 (40%) 0.4520
 Females 7 3 (43%) 4 (57%)
Site 21
 Frontal 14 6 (43%) 8 (57%) 0.1974
 Temporal 4 2 (50%) 2 (50%)
 Occipital 3 3 (100%) 0 (0%)
Grading 22
 II 12 4 (33%) 8 (67%) 0.0286
 III 10 8 (80%) 2 (20%)
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with the stemness marker Nestin (Figure 4E and data not 
shown). PATZ1 expression here appears mainly nuclear 
but a speckled cytosolic expression can be observed as 
previously described in other cancer cell types [20-22].
We also used the GBM cell lines U87MG to isolate 
GSC and analyze PATZ1 expression in comparison with 
matched bulk and differentiated cells (Supplementary 
Figure 1). PATZ1 protein expression resulted enriched in 
Figure 2: Immunoreactivity score in GBMs and oligodendrogliomas stained for PATZ1. (A) Representative GBM scored 
0. (B) Representative GBM scored +. (C) Representative GBM scored ++. (D) Representative GBM scored +++. (E) Representative 
oligodendroglioma scored 0. (F) Representative oligodendroglioma scored +. (G) Representative oligodendroglioma scored ++. (H) 
Representative oligodendroglioma scored +++. Original magnification: 40x.
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Table 2: Correlations between PATZ1 and the proneural and mesenchymal signature in GBMa
Proneural signature Mesenchymal signature
Gene rb p gene r p
CHD7 0.649 3.9e-62 HEXB -0.597 3.8e-50
CSNK1E 0.633 3.1e-58 SQRDL -0.583 2.7e-47
MARCKSL1 0.592 4.4e-49 TMBIM1 -0.537 4.1e-39
SOX4 0.580 7.1e-47 IL15 -0.535 7.1e-39
NOTCH1 0.574 1.0e-45 RAB32 -0.528 1.0e-37
MAP2 0.564 9.4e-44 ANXA4 -0.524 5.1e-37
SOX11 0.557 1.1e-42 S100A4 -0.523 5.7e-37
DLL3 0.549 3.8e-41 FCGR2B -0.522 1.0e-36
PODXL2 0.545 1.3e-40 RRAS -0.518 4.4e-36
MMP16 0.539 1.4e-39 P4HA2 -0.513 2.2e-35
FXYD6 0.535 6.9e-39 VAMP5 -0.505 3.8e-34
TOP2B 0.532 1.8e-38 NPC2 -0.499 2.7e-33
PHF16 0.532 2.2e-38 CAST -0.497 6.3e-33
SEZ6L 0.526 2.1e-37 PLS3 -0.497 4.7e-33
BCAN 0.524 4.0e-37 COPZ2 -0.495 1.1e-32
CRMP1 0.519 3.1e-36 PLAUR -0.495 9.4e-33
NLGN3 0.518 4.2e-36 CLEC2B -0.490 5.4e-32
WDR6 0.511 3.9e-35 LGALS3 -0.477 3.9e-30
PHLPP1 0.500 1.8e-33 LY96 -0.476 5.6e-30
MTSS1 0.494 1.5e-32 CLIC1 -0.475 6.1e-30
OLIG2 0.494 1.6e-32 PIGP -0.473 1.1e-29
NRXN2 0.488 1.2e-31 ALOX5 -0.466 1.0e-28
PAFAH1B3 0.488 1.2e-31 TNFAIP8 -0.465 1.3e-28
DBN1 0.484 4.1e-31 CSTA -0.461 4.3e-28
MMP15 0.483 5.8e-31 S100A11 -0.461 5.0e-28
FLRT1 0.479 1.8e-30 CTSB -0.453 4.9e-27
DPF1 0.479 1.9e-30 CASP4 -0.453 4.5e-27
ASCL1 0.479 1.7e-30 ANXA2 -0.447 2.9e-26
CRB1 0.476 5.3e-30 RAB27A -0.442 1.1e-25
DCX 0.472 1.5e-29 MGST2 -0.440 1.9e-25
SATB1 0.472 1.6e-29 SP100 -0.439 2.7e-25
ZNF510 0.471 2.1e-29 ARPC1B -0.437 4.6e-25
RUFY3 0.467 7.5e-29 TLR2 -0.437 4.4e-25
GNG4 0.467 7.8e-29 ASL -0.433 1.6e-24
MYT1 0.461 5.1e-28 KYNU -0.433 1.3e-24
(Continued )
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Proneural signature Mesenchymal signature
Gene rb p gene r p
CASK 0.451 9.9e-27 PROCR -0.433 1.7e-24
CDK5R1 0.446 4.4e-26 FHL2 -0.433 1.4e-24
VAX2 0.442 1.1e-25 LGALS1 -0.432 2.1e-24
GSK3B 0.436 5.9e-25 TIMP1 -0.432 1.8e-24
NCAM1 0.430 3.7e-24 PHF11 -0.432 2.1e-24
MAPT 0.429 4.5e-24 MAN1A1 -0.425 1.3e-23
CKB 0.425 1.4e-23 AMPD3 -0.424 1.5e-23
CBX1 0.425 1.3e-23 POLD4 -0.418 7.2e-23
KIF21B 0.425 1.3e-23 CYBRD1 -0.418 7.1e-23
MYO10 0.424 1.6e-23 CHI3L1 -0.418 7.9e-23
NOL4 0.423 2.4e-23 IFI30 -0.416 1.2e-22
MPPED2 0.422 2.8e-23 FCGR2A -0.414 2.1e-22
BCOR 0.420 5.4e-23 ACSL1 -0.413 3.0e-22
CSPG5 0.419 6.0e-23 MAN2A1 -0.413 2.7e-22
CLASP2 0.414 2.3e-22 SYPL1 -0.412 3.7e-22
HMGB3 0.406 1.5e-21 IQGAP1 -0.405 2.4e-21
TMCC1 0.403 3.3e-21 RAC2 -0.403 3.6e-21
NKX2-2 0.400 7.1e-21 ICAM3 -0.402 4.3e-21
RALGPS1 0.400 7.1e-21 MS4A4A -0.401 6.6e-21
SOX2 0.399 9.7e-21 CRYZ -0.401 6.2e-21
GRIA2 0.399 1.0e-20 ANXA1 -0.400 8.2e-21
TTYH1 0.397 1.4e-20 PTGER4 -0.396 2.1e-20
ZNF184 0.397 1.5e-20 LTBP2 -0.396 2.2e-20
SCN3A 0.396 1.9e-20 SLC16A3 -0.395 2.4e-20
KLRC3 0.394 3.2e-20 NCF2 -0.393 3.8e-20
AMOTL2 0.391 6.6e-20 TGFBI -0.391 6.2e-20
TAF5 0.389 1.0e-19 MAFB -0.390 7.6e-20
DUSP26 0.383 3.8e-19 RHOG -0.388 1.4e-19
RAP2A 0.383 4.4e-19 CTSC -0.387 1.5e-19
CDC7 0.380 8.1e-19 SWAP70 -0.386 2.2e-19
SRGAP3 0.377 1.7e-18 IGFBP6 -0.383 4.1e-19
WASF1 0.375 2.4e-18 SERPINA1 -0.382 5.3e-19
ICK 0.372 5.2e-18 MFSD1 -0.382 5.6e-19
RAD21 0.371 6.4e-18 ACPP -0.381 6.1e-19
GSTA4 0.368 1.1e-17 TNFAIP3 -0.380 8.9e-19
SEC61A2 0.367 1.5e-17 IL1R1 -0.380 8.3e-19
(Continued )
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Proneural signature Mesenchymal signature
Gene rb p gene r p
EPHB1 0.364 2.8e-17 SYNGR2 -0.377 1.6e-18
DPYSL4 0.363 3.3e-17 CASP8 -0.376 1.9e-18
NRXN1 0.360 6.5e-17 C5AR1 -0.375 2.4e-18
PDGRA 0.352 3.6e-16 CTSZ -0.375 2.6e-18
ERBB3 0.352 3.8e-16 ARHGAP29 -0.369 9.6e-18
ABAT 0.350 5.3e-16 SHC1 -0.366 1.8e-17
GADD45G 0.345 1.4e-15 SERPINE1 -0.366 1.7e-17
CDC25A 0.341 3.7e-15 MSR1 -0.366 1.9e-17
ATP1A3 0.338 5.8e-15 FXYD5 -0.365 2.2e-17
YPEL1 0.336 9.6e-15 THBD -0.364 2.8e-17
FBXO21 0.335 1.1e-14 LAIR1 -0.363 3.6e-17
ARHGEF9 0.335 1.1e-14 CD14 -0.359 8.9e-17
HDAC2 0.331 2.2e-14 GRN -0.358 1.1e-16
ZNF248 0.328 4.3e-14 PTPRC -0.354 2.6e-16
FHOD3 0.324 8.5e-14 LY75 -0.353 3.1e-16
HOXD3 0.320 1.9e-13 GNA15 -0.350 5.6e-16
TSAPN3 0.318 2.8e-13 VDR -0.349 7.1e-16
TOPBP1 0.318 3.0e-13 CASP1 -0.349 6.3e-16
EPB41L5 0.317 3.1e-13 ITGB2 -0.346 1.4e-15
BEX1 0.316 3.9e-13 PTPN22 -0.345 1.7e-15
DGKI 0.314 5.7e-13 EMP3 -0.345 1.7e-15
STMN1 0.314 6.1e-13 TCIRG1 -0.344 1.8e-15
CA10 0.308 1.7e-12 SLAMF8 -0.344 2.0e-15
MCM10 0.307 1.9e-12 SIGLEC7 -0.344 1.7e-15
P2RX7 0.305 3.0e-12 ITGAM -0.338 5.7e-15
PDE10A 0.295 1.6e-11 SCPEP1 -0.336 8.8e-15
FGF9 0.293 2.2e-11 TGFBR2 -0.333 1.5e-14
RAB33A 0.293 2.1e-11 STAT6 -0.333 1.6e-14
TMEM35 0.290 3.6e-11 LILRB2 -0.332 2.1e-14
GRID2 0.290 3.6e-11 SIGLEC9 -0.330 3.0e-14
PPM1D 0.288 4.8e-11 PLAU -0.324 8.6e-14
PAK7 0.286 6.6e-11 ARSJ -0.324 9.5e-14
NANOG 0.284 1.0e-10 SEC24D -0.323 1.1e-13
PPM1E 0.280 1.8e-10 TRIM38 -0.319 2.3e-13
MAST1 0.279 2.2e-10 ELF4 -0.318 2.7e-13
a All the genes belong to either the proneural or mesenchymal signatures as described by Verhaak et al. [7].
b Correlations were analyzed by Pearson’s χ2 test through the R2 platform (http://r2.amc.nl). For more correlations between 
PATZ1 and the mesenchymal signature see Supplementary Table 5.
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Figure 3: In silico meta-analysis of PATZ1 expression in human GBM tissues and cell lines. (A) Box-plot comparing 
PATZ1 expression in normal brain (NB) and gliomas of different grade (G). The data were analyzed by one-way analysis of variance 
(ANOVA) through the R2 web platform. (B) Box-plot showing PATZ1 expression in the different GBM subtypes and statistical analysis of 
the differences among them. C = classical, M = mesenchymal, N = neural, P = proneural. The data were analyzed by one-way analysis of 
variance (ANOVA) through the R2 web platform. (C) On the left, YY-plot in GSCs (ordered by PATZ1 expression). The cells are divided 
in two group as indicated in the figure. On the right, box-plot comparing PATZ1 expression in the two groups. (D) YY-plot correlating 
PATZ1 and PROM1 expression in stem cells derived from GBM (n = 7), oligoastrocytoma (n = 2), normal human foetus (n = 5) and primary 
biopsies of non-malignant brain tissue (n = 6). Significance of correlation (inbox) was analyzed by Pearson’s χ2 test through the R2 web 
platform (http://r2.amc.nl). (E) Box-plot comparing PATZ1 expression in primary GBM sorted for Cd133 expression (negative/positive). 
The data were analyzed by one-way analysis of variance (ANOVA) through the R2 web platform. *, p < 0.05; **, p < 0.01; ***, p < 0.001; 
****, p < 0.0001. Datasets for each cohort of samples are indicated in the figure with the relative reference in brackets. 2log of PATZ1 = 
logarithmic values of PATZ1 expression with base of 2.
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GSC versus both bulk and differentiated matched cells 
and correlated with expression of platelet-derived growth 
factor receptor β (PDGFRβ), a stem cell-specific marker 
in human GBM [30].
To further confirm in vivo the association of 
PATZ1 with the stem cell compartment of the GBM, we 
performed immunofluorescence labeling with antibodies 
anti-PATZ1 and GSC markers, including NESTIN and 
OCT-4, in 5 GBMs positive for PATZ1 expression. As 
shown in Figure 5, PATZ1 (red nuclear signal) was co-
expressed with NESTIN (green cytoplasmic signal) 
in a sub-population of neoplastic cells. In these cells 
co-localization of OCT-4 (green nuclear signal) with 
PATZ1 was also evident.
PATZ1 expression levels predict survival of 
GBM patients
The proneural GBM subtype is characterized by a 
trend toward longer survival, but is totally unresponsive 
Figure 4: PATZ1 expression in GSC cultures. (A) Representative phase contrast pictures of human glioma cells cultured in media 
selective (GSC, right panels) or not (DIFF, left panels) for the growth of glioma stem cells. The upper-right panel displays GSC growing 
as neurosphere, while the lower-right panel displays GSC growing in adhesion. Scale bar: 100μm. (B) Gene expression changes of PATZ1 
in human glioma cells grown in media selective (GSC) or not (DIFF) for the growth of GSC, as assessed by qRT-PCR. Data are presented 
as mean ± SD. (C) Gene expression changes of PATZ1 in GSC growing in adhesion (adherent) or in suspension (sphere), as assessed by 
qRT-PCR. Data are presented as mean ± SD. (D) Representative immunofluorescence images depicting in yellow the expression of OCT4, 
NANOG, SOX-2, and NESTIN in GSC growing either in adhesion (GSC adherent, lower panels) or in suspensions (GSC sphere, upper 
panels). Nuclei are depicted by the blue fluorescence of DAPI. Scale bar: 20 μm. (E) Representative confocal immunofluorescence image 
(merge image) showing the expression of PATZ1 (yellow fluorescence) and Nestin (red fluorescence) in GSCs. Nuclei are depicted by the 
blue fluorescence of DAPI. Single immunodetection of either PATZ1 or Nestin in the inset area, and digital merge of the images, are shown 
in the middle. Negative control obtained by omitting the primary antibodies is shown on the right. Scale bar: 20 μm.
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to aggressive treatment with concurrent chemo- and 
radiotherapy [7]. Consistent with the enrichment of PATZ1 
in the proneural subtype, we showed in our local cohort 
of gliomas, that patients with low PATZ1 score (0/+) had 
a worse overall survival (OS) than patients with high 
PATZ1 score (++/+++) (HR = 2.525, 95% CI = 1.208-
5.280, p = 0.0138) (Figure 6A). The median OS for 16 
patients with high PATZ1 was 36 months, in contrast to 
12 months for 28 patients with low or absent PATZ1. 
Similarly, when we extended survival analyses to a larger 
cohort of GBM samples (n = 85), in which all subtypes 
were similarly represented (GBM – TCGA - 540), both 
OS and progression-free survival (PFS) were significantly 
correlated to PATZ1 expression, being worse in patients 
expressing low levels of PATZ1 (Supplementary Figure 
2). In this same cohort of samples proneural GBMs have 
longer survival compared with mesenchymal subtype 
(Supplementary Figure 2, Panel C). Interestingly, also 
when we restricted the analysis to the proneural subset 
of GBM, Kaplan-Meier survival curves, followed by log-
rank test, showed that PATZ1 expression stratifies these 
patients (n = 24) in two statistically different subgroups 
where low PATZ1 has worse OS (HR = 3.191, 95% CI = 
2.355-14.31, p = 0.001) and PFS (HR = 3.595, 95% CI 
= 2.785-19.06, p = 0.0006) (Figure 6B–6C). The median 
OS for 10 patients with high PATZ1 expression was 53 
months, in contrast to 10 months for 14 patients with low 
PATZ1. Even more strikingly, the median PFS for patients 
with high PATZ1 was 63 months versus 6 months for 
patients with low PATZ1. Moreover, the 5-year PFS was 
about 40% for proneural GBM patients with high PATZ1 
versus 0 with low PATZ1. In the same group of patients, 
using a multivariate Cox regression analysis, including 
known prognostic factors, such as age at diagnosis and 
methylation of the MGMT gene, low expression of PATZ1 
resulted an independent prognostic factor for OS survival 
(HR= 0.2886, 95% CI = 0.0982-0.8482, p = 0.0246) and 
PFS (HR = 0.2458, 95% CI = 0.0802-0.7534, p = 0.0146).
These data suggest that PATZ1 expression has a 
crucial impact on outcome of GBM patients with a proneural 
classification, and could be used as an independent prognostic 
marker to predict survival and response to treatment.
PATZ1 downregulates CXCR4 expression in 
GBM
Remarkably, low PATZ1 samples shown in Figure 
6B and 6C were mostly characterized (11 out of 14) by 
increased expression of the G-protein coupled receptor 
CXCR4 (Supplementary Table 5), which has been shown 
to induce and assist in the maintenance of a mesenchymal 
expression profile in GBM cells [31] and is overexpressed 
in CD133+ cells from human GBMs resistant to 
chemotherapy [32]. Indeed, we found that CXCR4 was 
a high significant prognostic and predictive factor in 
proneural GBM, were high CXCR4 patients show worse 
Figure 5: PATZ1 localization in the stem cell compartment of GBM. Representative confocal microscopy images of GBM (two 
samples with high PATZ1 score (+++) and GBM-associated normal tissues stained with anti-NESTIN (A, E), anti-OCT-4 (I) and anti-
PATZ1 (B, F, J). (D, H, L) Merge images showing co-localization of PATZ1 with either NESTIN or OCT-4. Scale bar: 20 μm. (C, G, K) 
Nuclei are depicted by the blue fluorescence of DAPI.
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outcome considering both OS and PFS survival curves 
(Figure 7A–7B), and negatively correlated with PATZ1 in 
these patients (r = -0.449; p = 0.03) (Figure 7C). A similar 
negative correlation between PATZ1 and CXCR4 was also 
observed in GSCs (Supplementary Figure 3).
In order to investigate a possible role of PATZ1 in 
downregulating CXCR4 gene expression in GBM cells, 
we transiently transfected the VS-GB cells, a GBM-
derived primary cell line that does not express PATZ1, 
with a plasmid expressing PATZ1, and measured CXCR4 
mRNA and protein levels by qRT-PCR and western blot, 
respectively (Figure 7D). A significant decrease of both 
mRNA and protein levels was observed in cells expressing 
PATZ1 compared to empty vector-transfected control, 
supporting an inhibitory role of PATZ1 on CXCR4 
expression. This is consistent with data extracted from the 
Trafac homology server, showing that the CXCR4 promoter 
harbor consensus sequence for PATZ1 [33], and with data 
extracted from our previous analysis of Patz1-knockout 
mouse embryonic fibroblasts [34], showing that Patz1-
null mouse embryonic fibroblasts express a 4-fold change 
increase of Cxcr4 compared to wild-type littermate controls.
DISCUSSION
One of the most important hallmarks of GBM is 
the marked heterogeneity within and across these tumors, 
which has been attributed to cancer cell plasticity [35]. 
According to the cancer stem-cell model some cancers 
are organized into a hierarchy of subpopulations of 
tumorigenic cancer stem cells, which drive tumor 
growth, therapy resistance and disease progression. It 
is therefore imperative to clarify the markers that can 
be used to identify these cells and the context in which 
they work [36]. It has been recently proposed that 
patient-derived glioblastoma stem-like cells (GSCs) can 
be sub-divided in two main groups, one characterized 
by a proneural-like phenotype and the other showing a 
mesenchymal-like phenotype according to the molecular 
subtype classification of the TCGA [7–8]. Phenotypically, 
proneural GSCs exhibit non-adherent sphere forming 
growth in vitro and circumscribed, non-invasive growth 
in vivo. In contrast, mesenchymal cells grow semi-
adherently in vitro and show invasive growth in vivo [8, 
37]. Accordingly, patients with proneural GBM have a 
Figure 6: PATZ1 expression negatively correlates with worse survival in GBM patients. (A) Overall (OS) Kaplan-Meier 
survival curves of GBM patients shown in Supplementary Table 1 stratified by protein levels of PATZ1, as indicated. (B) OS and (C) 
progression-free (PFS) Kaplan-Meier curves of the proneural subset of GBM patients from the TCGA data set shown in Figure 4B. Note 
that patients with lower PATZ1 expression have a worse survival rate than patients with higher PATZ1 as assessed by log-rank test.
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trend toward longer survival [7], whereas patients with 
mesenchymal GBM show the worst outcome [38].
In this study we analyzed expression of the 
Kruppel-type Zinc Finger transcription factor PATZ1 
in GBM and oligodedrogliomas, finding it was highly 
expressed in a significant number of cases, whereas it 
was undetectable in normal glia. Moreover, we showed 
that PATZ1 is expressed in GSCs both in vitro (in GBM-
derived stem cells) and in vivo (human tissue specimens), 
is downregulated in differentiated cells from the same 
tumor as compared to GSCs, and its expression is higher 
in GSCs growing as spheres (likely proneural) than in 
GSCs growing as adherent cells (likely mesenchymal). 
These observations were validated and completed 
in independent glioma datasets, finding a significant 
overlap of high PATZ1 expression with the proneural 
subtype and conversely of low PATZ1 expression with 
the mesenchymal subtype in both GBMs and GSCs. 
Since PATZ1 has been described as an inhibitor of cell 
proliferation in some cancer cell contexts [13,20,39], we 
would expect that GSCs growing as spheres that express 
higher levels of PATZ1 compared to GSCs growing in 
adhesion may proliferate less. However, since there are 
no differences in the proliferation rate between GSCs 
growing as spheres and those growing as adherent 
cells [26], we concluded that PATZ1 is not associated 
with proliferation in these cells. Interestingly, confocal 
microscopy analysis of human GBM specimens showed 
that PATZ1 was expressed in the NESTIN+ subpopulation, 
which has been recently shown to be crucial for tumor 
recurrence after treatment with the chemotherapeutic 
agent temozolomide [10].
Finally, we characterized the prognostic impact 
of PATZ1 expression first in our local cases of GBM, 
Figure 7: CXCR4 expression correlates positively with worse survival and negatively with PATZ1 in proneural GBM 
patients. (A) Overall (OS) and (B) progression-free (PFS) Kaplan-Meier survival curves of the patients shown in Figure 7B-7C (proneural 
subset of the TCGA dataset of GBM). Note that patients with higher CXCR4 expression have worse survival rates than patients with lower 
CXCR4, as assessed by log-rank test. (C) YY-plots correlating PATZ1 and CXCR4 expression in the proneural GBMs shown in A and B. 
Significance of correlation (inbox) was analyzed by Pearson’s χ2 test through the R2 web platform (http://r2.amc.nl). (D) VS-GB cells 
were transiently transfected with 10 μg PATZ1 expressing plasmid, and endogenous CXCR4 mRNA was measured 48h later by qRT-PCR. 
CXCR4 mRNA levels were normalized for endogenous β-actin levels. The mean ± SE of three independent experiments, each in duplicate, 
is reported. ***, P = 0.001. PATZ1 and CXCR4 protein expression is shown on the top by western blot analysis, using vinculin detection 
as a loading control. Densitometric analysis by Image J software was applied: relative expression levels of CXCR4, compared to empty 
vector-transfected control and normalized with respect to vinculin, are indicated on the top of the blot.
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finding a significant worse outcome in patients showing 
absent or low levels of PATZ1 (< 10% positive cells), 
suggesting it may be used as a prognostic marker. Then, 
extending the analysis to the TCGA dataset, including 
samples subclassified in the four subtypes described by 
Verhaak et al. [7], the capacity of PATZ1 to discriminate 
GBM patients with different prognosis was significantly 
shown also in the proneural subtype, where low levels 
of PATZ1 correlate with worse outcome in both overall 
and progression-free survival curves, independently 
from other known prognostic factors, such as MGMT 
promoter methylation and age at diagnosis. Therefore, 
despite PATZ1 is enriched in the proneural subtype, there 
are proneural GBMs that express low levels of PATZ1 
that are associated with a shorter patients survival. This 
is consistent with the already described intra-subtype 
heterogeneity of GBMs, which highlights the importance 
of finding new markers able to further sub-classify each 
subtype [35].
Since PATZ1 loss/downregulation has been 
associated with the acquisition of a mesenchymal 
phenotype in cancer cells [20], and the mesenchymal 
phenotype in GBMs is associated with the poorest 
prognosis and most aggressive phenotype, with advantage 
in proliferative capacity and neovascularization [5, 38], 
we speculate that a subset of proneural GBMs may be 
more aggressive due to the downregulation of PATZ1 
and consequent activation of a mesenchymal program. 
Consistent with this hypothesis, we found that in the 
proneural subset there was a 75% of negative concordance 
(r = -0.44; p = 0.03) between PATZ1 and CXCR4, whose 
overexpression is an outcome common to multiple 
mechanisms of Epithelial-Mesenchymal Transition (EMT) 
induction in GBM and directly involved in determining 
the EMT phenotype [40]. Interestingly, according to the 
Trafac homology server, the CXCR4 promoter harbors 
consensus sequence for PATZ1 [33], and Patz1-null 
mouse embryonic fibroblasts express a 4-fold change 
increase of Cxcr4 compared to wild-type littermate 
controls [34]. Therefore, it is possible that PATZ1 could 
be directly involved in CXCR4 silencing. Indeed, it 
has been hypothesized that factors associated with the 
more stem-like phenotype may account for CXCR4 
expression in GBM [27], and we provided evidence that 
PATZ1 could be one of these factors: in VS-GB cells, a 
primary GBM cell line that does not express endogenous 
PATZ1, overexpression of PATZ1 leads to downregulation 
of CXCR4. Further experiments are ongoing in our 
laboratory to explore the possibility of a direct role of 
PATZ1 on the CXCR4 promoter in GBM as well as in 
other cancer-derived cell lines, where PATZ1 appears 
involved in counteracting EMT. According to current 
opinions envisaging a parallel between dedifferentiation 
of cancer cells and reprogramming of somatic cells [41], 
the transdifferentiation of tumor cells from proneural to 
mesenchymal may imply a reprogramming process that 
leads differentiated cells to reacquire the capacity to 
differentiate into different cells. This is consistent with our 
previous results showing that PATZ1 plays an inhibitory 
role in the reprogramming process [34], and suggests a 
potential PATZ1 inhibitory role on the transition from 
the proneural to the mesenchymal phenotype. However, 
further functional experiments are needed to demonstrate 
the involvement of the PATZ1-CXCR4 axis in the 
proneural-to-mesenchymal phenotipic switch.
In conclusion, we describe PATZ1 as a novel 
biomarker of GBM and GSCs, differentially expressed 
among GBM and GSC subtypes and able to further 
subdivide the proneural GBM subtype in two populations 
with different overall and progression free survival. As 
PATZ1 has been proven an important transcription factor 
involved in stem cell pluripotency [12], it is encouraging 
to see that the proneural type of GBM, characterized by 
a stem-like signature, has higher expression of PATZ1 
compared to other types. Finally, this finding may explain 
the paradox that the proneural type of GBM resists standard 
therapeutic caused by the cancer stem cells maintained by 
PATZ1 involved transcription factor networks, while at the 
same time PATZ1 restricts the proneural type of GBM to 
differentiation into mesenchymal type.
MATERIALS AND METHODS
Tissue specimens
45 patients diagnosed with glioblastoma and 22 with 
oligodendroglioma were included in the study. They had 
all undergone a complete excision of the tumor at first 
surgery. All the cases were identified between 2004 and 
2013 and the diagnoses were made in accordance with 
the 2007 WHO classification [42]. This time interval was 
chosen in order to ensure a clinical follow-up period of at 
least 2 years for each identified case. All the cases were 
reviewed to evaluate adequate representative formalin-
fixed paraffin-embedded tissue in order to perform 
immunohistochemical assay. We excluded those cases for 
which data of outcome were unavailable and for which 
diagnostic tissue was insufficient. Informed consent for 
the scientific use of biological material was obtained from 
all patients and the work has been approved by the local 
Ethical Committee (CEI 203/15 of 12/11/2015).
Immunohistochemical analysis
4 μm sections were used for immunohistochemistry. 
Sections were dewaxed in xylene, hydrated in graded 
series of alcohol and subjected to heat-induced antigen 
retrieval. After blocking endogenous peroxidase 
activity, the tissue was incubated with antibody anti-
PATZ1 (polyclonal rabbit, R1P1 [22]; 1: 500 dilution, 
overnight incubation). Subsequently, the slices were 
rinsed and incubated with the biotinylated secondary 
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antibody, at room temperature, for 30 minutes. The 
bound antibody complexes were stained for 3-5 minutes 
or until appropriate for microscopic examination with 
diaminobenzidine, and slides were then counterstained 
with hematoxylin (30s) and mounted. All slices were 
reviewed by two experienced pathologists (M.L.D., E.G.).
The assessment of PATZ1 (nuclear) staining was 
based on the percentage of positive cells: no signal was set 
as “0”, ≤10% as “+”, >10% and <50% as “++” and ≥50% 
as “+++”. We defined high expression of PATZ1 as >10% 
of cells staining positive, and low expression as ≤10% of 
cells staining positive.
Immunofluorescence and confocal microscopy
For multiple-labeling immunofluorescence, tissues 
slides were dewaxed, hydrated and antigen retrieval was 
performed using Dewax and HIER Buffer L (Thermo 
Fisher Scientific, Cheshire, UK) as previously described 
[43]. They were incubated with the mixture of two primary 
antibodies anti-NESTIN (mouse monoclonal, sc23927, 
Santa Cruz Biotechnology, Santa Cruz, CA; 1:200 dilution, 
90 minutes incubation) and anti-PATZ1 (rabbit polyclonal, 
R1P1; 1: 500 dilution, overnight incubation) or anti PATZ1 
and anti-OCT-3/4 (mouse monoclonal, sc-5279 Santa Cruz 
Biotechnology; 1:100 dilution, 90 minutes incubation) in 
1% BSA in PBS-T in a humified chamber overnight at 4°C. 
Fluorescent secondary antibodies, raised against different 
species (Alexa Fluor 594, with red signal, against rabbit and 
Alexa Fluor 488, with green signal, against mouse), were 
used to locate the antigen/primary antibody complexes. 
Counter staining was made with Hoechst 33258 (nuclear 
blue staining) present in mounting medium (PBS:Glycerol 
= 1:1). Experiments were carried out on an inverted and 
motorized microscope (Axio Observer Z.1) equipped with 
a 63x/1.4 Plan-Apochromat objective. The attached laser 
scanning unit (LSM 700 4x pigtailed laser 405-639, Zeiss, 
Jena, Germany) enabled confocal imaging. For excitation, 
405 nm, 488 nm and 555 nm lasers were used. Fluorescence 
emission was revealed by MBS 405/488/555/639 for 
Hoechst 33258, Alexa Fluor 488 and Alexa Fluor 594. 
Triple staining immunoflourescence images were acquired 
separately in the blue, green and red channels at a resolution 
of 1024x1024 pixels, with the confocal pinhole set to one 
Airy unit and then saved in TIFF format.
To assess the stemness of GSCs, NANOG (rabbit 
polyclonal, ab80892 Abcam; 1:200 dilution), SOX-2 
(mouse polyclonal, AB5603 Millipore; 1:500 dilution), 
OCT-4 (rabbit polyclonal, sc-5279 Santa Cruz; 1:250 
dilution) and NESTIN (mouse monoclonal, 92590 
Chemicon; 1:100 dilution) expression was evaluated. 
PATZ1 (rabbit polyclonal, R1P1, 1:500 dilution) expression 
was analyzed as well. Briefly, cells were fixed in 4% 
paraformaldehyde for 20 minutes at room temperature 
(RT) and permeabilized for 10 minutes at RT with 0.1% 
Triton X-100 (Sigma-Aldrich) before exposing them to 
primary antibodies, that were incubated over-night at 4°C. 
Subsequently, Alexa Fluor 488 and Alexa Fluor 555 dyes 
labeled secondary antibodies against mouse and rabbit, 
respectively, diluted 1:800 in PBS, were employed for 1 
hour in a humidified chamber at 37°C (Molecular Probe, 
Invitrogen). Lastly, slides were mounted using Vectashield 
(Vector), as mounting medium, added with 0.1 μg/ml DAPI 
(Sigma) for nuclear staining. Images were acquired utilizing 
a live cell imaging dedicated system consisting of a Leica 
DMI 6000B microscope connected to a Leica DFC350FX 
camera (Leica Microsystems, Wetzlar, Germany) and 
equipped with a 63X/1.4 oil immersion objective or a 
40X/1.25 oil immersion objective. Adobe Photoshop 
software was utilized to compose and overlay the images 
and to adjust contrast.
Cell cultures and transfection
The independent ethic committee of the Azienda 
Ospedaliero-Universitaria of Udine has approved the 
research (Consents 102/2011/Sper and 196/2014/Em). 
Informed written consents were obtained from patients and 
all clinical investigations have been conducted according 
to the principles expressed in the Declaration of Helsinki.
GSCs (n=11) were isolated as previously described 
[44,45]. Briefly, human GBM samples were mechanically-
enzymatically dissociated and cells less than 40μm in 
diameter cultured on laminin-coated dishes in a growing 
medium composed as follows: Neurobasal-A medium 
(Gibco by Invitrogen, Carlsbad, CA), 2mM L-glutamine 
(Sigma-Aldrich, St. Louis, MO,), 1X N2 supplement 
(Gibco by Invitrogen), 25mg/ml Insulin, Penicillin-
streptomycin, 100mg/ml human apo-trasferrin (Sigma-
Aldrich), 1X B-27 supplement (Gibco by Invitrogen), 
20 ng/ml recombinant human basic fibroblast growth 
factor (h-FGF-basic) (Peprotech, Rocky Hill, NJ), 20 ng/
ml human epidermal growth factor (h-EGF) (Peprotech). 
Then cells were cultured in an incubator at 37°C, 
5%O2/5%CO2 and analyzed at the third passage in culture. 
From six GBM samples we isolated, in addition to GSCs, 
the matched non-stem tumor cells by growing dissociated 
cells in DMEM (Gibco by Invitrogen) supplemented with 
10% fetal bovine serum (FBS) (EuroClone, Pero, Italy) 
and 100 U/ml Penicillin 100 μg/ml Streptomycin. Cells 
were grown in an incubator at 37°C, 5%O2/5% CO2 and 
analyzed at the first passage in culture.
Human GBM U87MG (American Type Culture 
Collection, ATCC no. HTB-14), were grown in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% 
FBS. To obtain tumorspheres, U87MG cells were grown 
at low density (2000 cells/ml) in Stem cell medium (SM) 
[DMEM-F12 supplemented with 1% B27 (Sigma-Aldrich), 
10 ng/ml h-FGF (Sigma-Aldrich) and 20 ng/ml h-EGF 
(Sigma-Aldrich)] for 12 days. U87MG tumorspheres were 
induced to differentiate through the addiction of 10% FBS 
in SM medium. The cancer stem cell phenotype of these 
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cells was confirmed by assessing the expression of the 
stemness markers PDGFRß, NANOG and SOX-2.
VS-GB primary cell culture was derived from GBM 
specimens and grown as described previously [46]. They 
were transiently transfected by JetPRIME (Polyplus 
transfections, Illkirch, France) with 10 μg of HA-PATZ1 
plasmid encoding for PATZ1 variant 4 or 10 μg of the 
empty vector pCEFL-HA as negative control, according 
to manufacturer’s instruction.
RNA extraction and quantitative real time 
(qRT)-PCR
Total RNA from cells was purified by TRIzol 
(Invitrogen). After digestion of the residual genomic 
DNA by DNase I (Qiagen, Milano, Italy), RNA was 
reverse transcribed by SuperScript III cDNA synthesis 
kit (Invitrogen). cDNA was used to perform qPCR 
reactions with SYBR Green Master Mix gene expression 
kit (Biorad, Segrate, Italy) in 96-well plates with a 
LightCycler 480 system (Roche, Monza, Italy). The PCR 
conditions were as follow: 95°C for 3 minutes; 45 cycles 
at 95°C for 10 seconds, 60°C for 20 seconds and 72°C 
for 60 seconds. Primer pairs used (300 nm each) were as 
follows: PATZ1 (5’-TACATCTGCCAGAGCTGTGG-
3’/5’-TGCACCTGCTTGATATGTCC-3’); GAPDH (5’- 
GTCTCCTCTGACTTCAACAGCG-3’/5’-ACCACCCTG 
TTGCTGTAGCCAA-3’). CXCR4 (5’-TGAGAAG 
CATGACGGACAAG-3′/5’-AGGGAAGCGTGATGAC 
AAAG-3′); β-ACTIN (5’-CAAGAGATGGCCAC 
GGCTGCT-3’/5’-TCCTTCTGCATCCTGTCGGCA-3’). 
Gene expression changes were calculated using the 
2(-Delta Delta C(T)) method [47].
Protein extraction and western blot analysis
Cells were lysed in buffer containing 1% Nonidet 
P-40, 1 mmol/liter EDTA, 50 mmol/liter Tris-HCl (pH 7.5), 
and 150 mmol/liter NaCl supplemented with Complete 
protease inhibitors (Roche). Total proteins were resolved in 
a 10-12% polyacrylamide gel under denaturing conditions 
and transferred to nitrocellulose filters for Western blot 
analyses. Membranes were blocked with 5% BSA in TBS 
and incubated with the primary antibodies. Membranes were 
then incubated with the horseradish peroxidase–conjugated 
secondary antibody (1:3.000) and the reaction was detected 
with a Western blotting detection system (enhanced 
chemiluminescence; GE Healthcare). The primary 
antibodies used were: anti-PATZ1 [22]; anti-NESTIN (sc-
23927, Santa Cruz Biotechnology, Santa Cruz, CA); anti-
PDGFRβ (3169, Cell Signaling Technology, Boston, MA); 
anti-NANOG (sc-134218, Santa Cruz Biotechnology); anti-
SOX2 (sc-20088, Santa Cruz Biotechnology); anti-CXCR4 
(C8727, Sigma-Aldrich). To ascertain that equal amounts 
of protein were loaded, the membranes were incubated 
with anti-ACTIN (sc-1616-R, Santa Cruz Biotechnology) 
or anti-VINCULIN (sc-7649, Santa Cruz Biotechnology) 
antibodies.
Data mining
For PATZ1 mRNA expression analysis and correlation 
with clinical, molecular and cell phenotype, the Genomics 
Analysis and Visualization platform (http://r2.amc.nl) 
was used with the following datasets: 1) GSE9385 [25], 
including 6 adult non diseased brain, 26 glioblastomas 
and 21 oligodendrogliomas,; 2) GSE8049 [26], including 
9 different glioblastoma-derived neurosphere cultures in 
two biological replicates; 3) GSE15209 [28], including 
stem cells derived from 7 GBMs, 2 oligoastrocytomas, 5 
normal fetuses and primary biopsies from 6 normal brains; 
4) GSE18015 [29], including 8 gliomas sorted for CD133 
expression; 5) the TCGA dataset Tumor Glioblastoma - 
540 - MAS5.0 - u133a (n = 540) (http://cancergenome.nih.
gov), including 85 samples sub-classified in classical (n = 
17), mesenchymal (n = 27), neural (n = 17) and proneural 
(n = 24) GBM [7], to correlate PATZ1 expression to GBM 
subtype and specific gene signatures. The last dataset was 
also used for Overall and Progression-free survival analysis 
using the scan cut-off mode based on median PATZ1 
expression and specifying the proneural track subset.
Statistical analysis and Kaplan-Meier survival 
curves
The Fisher’s exact test was used to evaluate the 
correlations between PATZ1 score and the clinical 
variables (age, gender, site, oligodendroglioma grading).
All correlations within the TCGA and other public 
datasets were assessed by Pearson’s χ2 test or one-way 
analysis of variance (ANOVA), through the R2 platform 
(http://r2.amc.nl).
Kaplan-Meier survival curves were used to 
analyze OS and PFS, and statistical significance 
was assessed by the log-rank test. In Figure 6A, the 
stratification of High/Low PATZ1 was based on the 
percentage of cells expressing nuclear PATZ1 protein by 
immunohistochemistry (High: > 10%; Low: < 10%). The 
stratification of High/Low PATZ1 and High/Low CXCR4 
in the TCGA dataset was based on RNA expression 
using a cutoff of 100.6 and 197.7, according to the scan 
function of the R2 platform used, where an optimum 
survival cutoff is established based on statistical testing 
(log-rank test).
PATZ1 expression on human derived stem cells was 
expressed as mean ± standard deviation. Comparisons 
between two groups were performed by paired or unpaired 
t test, as appropriate.
All statistical analyses were performed using 
GraphPad Prism 5 software (GraphPad Software, La Jolla, 




GBM, glioblastoma; GSCs, glioma-initiating stem 
cells; TCGA, The Cancer Genome Atlas; PATZ1, POZ, 
AT-hook and zinc-finger 1; OS, overall survival; PFS, 
progression-free survival; EMT, epithelial-mesenchymal 
transition; RT, room temperature; h-FGF-basic, human 
basic fibroblast growth factor; h-EGF, human epidermal 
growth factor; FBS, fetal bovine serum; DMEM, 
Dulbecco’s modified eagle medium; SM, stem cell 
medium; IHC, immunohistochemistry.
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